Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1(st) International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
- Author(s)
- Bewersdorf, JP; Xie, Z; Bejar, R; Borate, U; Boultwood, J; Brunner, AM; Buckstein, R; Carraway, HE; Churpek, JE; Daver, NG; Porta, MGD; DeZern, AE; Fenaux, P; Figueroa, ME; Gore, SD; Griffiths, EA; Halene, S; Hasserjian, RP; Hourigan, CS; Kim, TK; Komrokji, R; Kuchroo, VK; List, AF; Loghavi, S; Majeti, R; Odenike, O; Patnaik, MM; Platzbecker, U; Roboz, GJ; Sallman, DA; Santini, V; Sanz, G; Sekeres, MA; Stahl, M; Starczynowski, DT; Steensma, DP; Taylor, J; Abdel-Wahab, O; Xu, ML; Savona, MR; Wei, AH; Zeidan, AM;
- Journal Title
- Blood Reviews
- Abstract
- Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including germline predisposition, epigenetic and immune dysregulation, the complexities of clonal hematopoiesis progression to MDS, as well as novel animal models of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and immune checkpoint inhibitors. While some of these agents have entered clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.
- Publisher
- Elsevier
- Keywords
- Animals; Humans; *Neoplasms; *Myelodysplastic Syndromes/etiology/therapy; Epigenomics; Cell- and Tissue-Based Therapy; Protein Processing, Post-Translational; Animal models; Genetics; Immunology; Mds; Myelodysplastic syndrome; Novel therapies
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 36934059
- Publisher's Version
- https://doi.org/10.1016/j.blre.2023.101072
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-03-29 08:33:59
Last Modified: 2023-07-12 08:28:28